The SUM-185PE cell line was derived from a pleural effusion metastasis of a patient with metastatic breast cancer that was ER and PR negative. While this cell line was a mystery to us for several years because none of the classic breast cancer oncogenes were altered in these cells, our functional genomic analysis of these cells shed tremendous light on the biology of the cells, including a complete functional genomic signature, the KEGG canonical pathways that are of importance to the biology of these cells, and the identification of a targeted therapeutic strategy that results in profound and specific loss of cell survival. As a direct result of these studies, we discovered that SUM-185PE cells have a focal amplification involving the FGFR3 gene that is a driving oncogene in these cells and the cells are, as a result, highly sensitive to FGFR targeted drugs. This cell line is an outstanding example of how genomic and functional genomic data can be leveraged to uncover the deep biology of a cancer cell line, and to identify a strategy to reverse engineer the cells in a highly specific manner.
Okay, let’s delve more deeply into the SUM-185 cell line.
- Derivation of the SUM-185PE cell line
- Narrative Summary of the SUM-185 cell line
- The oncogene signatures of this cell line
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
- Functional-druggable signature for SUM-185 cells
- Differential drug sensitivity data from Heiser et al.
- Bibliography of published papers in which SUM-185 cells were used
- SUM-185 blog page
Back to the SUM cell line Gateway Page
Back to SUM-line Knowledge Base Home page
